Afarak Group SE
CHANGES REGARDING AFARAK GROUP SE’S TREASURY SHARES
CHANGES REGARDING AFARAK GROUP SE’S TREASURY SHARES
14:45 London, 00:00 Helsinki, 31 March 2025 - Afarak Group SE ("Afarak" or "the Company") (LSE: AFRK, NASDAQ: AFAGR)
CHANGES REGARDING AFARAK GROUP SE’S TREASURY SHARES
Stock Exchange Release
Pursuant to the share issue authorization granted by the Company's Annual General Meeting held on May 31, 2024, the Board of Directors has resolved on a directed share issue without payment. Based on the share issue 400,000 of the Company's treasury shares (“Shares”) have now been transferred to CEO Guy Konsbruck. The Shares form a part of the remuneration package under the CEO agreement.
After the execution of the share issue 15,641,514 treasury shares shall remain in the possession of Afarak, representing approximately 5.65 per cent of the total shares and votes of the Company.
Helsinki, March 31, 2025
AFARAK GROUP SE
Board of Directors
For additional information, please contact:
Afarak Group SE
Guy Konsbruck, CEO, +356 2122 1566, guy.konsbruck@afarak.com
Financial reports and other investor information are available on the Company's website: www.afarak.com.
Afarak Group is a specialist alloy producer focused on delivering sustainable growth with a Speciality Alloys business in southern Europe and a FerroAlloys business in South Africa. The Company is listed on NASDAQ Helsinki (AFAGR) and the Main Market of the London Stock Exchange (AFRK).
Distribution:
NASDAQ Helsinki
London Stock Exchange
Main media
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Gluco Tonic2.4.2025 04:46:19 CEST | Press release
GlucoTonic Reviews (DOCTOR INVESTIGATED): Is This Blood Sugar Breakthrough the Real Deal or Dangerous Hype
ProvaDent2.4.2025 03:18:11 CEST | Press release
ProvaDent Reviews (DENTIST INVESTIGATED): Can This Oral Probiotic Really Strengthen Teeth and Reverse Years of Damage?
Tenaris SA2.4.2025 00:05:53 CEST | Press release
Tenaris Files 2024 Annual Report / Annual Report on Form 20-F, and Convenes the Annual General Meeting of Shareholders and an Extraordinary General Meeting of Shareholders
INVENTIVA1.4.2025 23:00:00 CEST | Press release
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
Respilean1.4.2025 22:30:10 CEST | Press release
Respilean Review (BREAKING NEWS): Why Thousands Are Calling It the Natural Lung Breakthrough of 2025
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom